ASCO

The American Society of Clinical Oncology (ASCO) has accepted the Phase 1b dose expansion part of the OVM-200 Phase 1 trial for presentation at its annual meeting. Oxford, UK – 22nd May 2026 Press Release: OVM-200 Phase 1 clinical trial accepted for presentation at ASCO Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer is very pleased to announce that the Phase 1b dose expansion part of the Phase 1 trial of OVM-200 will be presented at the annua...